F8 and hemophilia: Despite these remarkable advances in hemophilia management over the past decade, challenges remain, including breakthrough bleeding, progressive joint disease, inhibitor development, lower efficacy of BPAs in inhibitor patients compared with FVIII/FIX replacement therapy in non-inhibitor patients, and QoL aspects.